Cargando…

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

INTRODUCTION: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. METHODS: U...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strasser-Weippl, Kathrin, Horick, Nora, Smith, Ian E, O’Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne M, Goss, Paul E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423419/ https://www.ncbi.nlm.nih.gov/pubmed/25888246 http://dx.doi.org/10.1186/s13058-015-0568-1

Ejemplares similares

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
por: Debiasi, Márcio, et al.
Publicado: (2018)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
por: Nielsen, Kåre, et al.
Publicado: (2023)

Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model
por: Goss, Paul E, et al.
Publicado: (2007)

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2013)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

In her family /
por: Metheny, Pat
Publicado: (1987)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
por: Schmidt, Marcus, et al.
Publicado: (2005)

ADVICE TO THE EXPECTANT MOTHER ON THE CARE OF HER HEALTH AND THAT OF HER CHILD
Publicado: (1947)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1947)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1943)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1941)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_umegdj7hk7adnbcnujtphfave0